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Objective: Although anticoagulation remains the mainstay of treatment for deep venous thrombosis, the use of inferior
vena cava (IVC) filters when anticoagulation has failed or when contraindicated remains a safe and effective treatment.
Greenfield (Boston Scientific, Natick, Mass) and TrapEase (Cordis, Bridgewater, NJ) filters are arguably among the most
popular filtration devices. The Greenfield filter (12F introducer) has been in use for>30 years and has been well studied.
The TrapEase filter (6F introducer) has been used since 2000, with a limited number of studies. Good guidelines to help
determine which filter to use in any given situation are lacking; therefore, this randomized study prospectively compared
the clinical outcomes (access-site thrombosis, filter thrombosis, and symptomatic pulmonary embolism [PE]) between
these filters.
Methods: Between July 2006 and November 2008, 156 patients (63 men, 93 women; mean age, 75 years; range, 38-101
years) were randomized: 84 to Greenfield and 72 to TrapEase IVC filter insertion in the infrarenal position using
angiographic guidance. Postoperative follow-up comprised serial lower extremity and IVC/iliac vein (IV) duplex
imaging (78.2%) at day 1, week 1, every 3 months for the first year, and every 6 months for the second year; clinical
evaluation, and clinic visits. During this period, 349 patients (143 men, 206 women; mean age, 75 years; range, 24-96
years) were not randomized.
Result: The indications for filter placement, in the 156 randomized patients, were gastrointestinal bleeding, 37;
intracranial hemorrhage, 12; free-floating clot, 19; failure of anticoagulation, 29; PE, 27; prophylactic, 4; and others, 32.
During a mean 12-month follow-up (range, 0-39 months), symptomatic IVC/IV thrombosis developed in five patients
(6.94%) in the TrapEase group and none in the Greenfield group (P .019). No filter migration, access-site thrombosis,
misplacement, or IVC perforation occurred. Recurrent PE was suspected in one of the five patients with IVC/IV
thrombosis. Overall mortality was 42.3% (66 patients), and 30-day mortality was 13.5% (21 patients: 10 TrapEase, 11
Greenfield). The study was initially designed to recruit 360 patients in both TrapEase and Greenfield filters in 2 years to
demonstrate any statistical significance but was prematurely concluded due to the interim results.
Conclusion: A higher rate of symptomatic IVC/IV thrombosis is associated with TrapEase filter placement. However, the
TrapEase filter still has a selective clinical role in the prevention of thromboembolism in selected patients who are
coagulopathic. This is the first randomized prospective study comparing IVC filters since their inception in 1967. (J Vasc
Surg 2010;52:394-9.)The safety and effectiveness of inferior vena cava (IVC)
filters in prevention of pulmonary embolism (PE) in high-
risk patients and when anticoagulation fails or is contrain-
dicated has been widely demonstrated.1-10 Several percuta-
neous IVC filtration devices have been developed and used.
Among those that are currently in use, Greenfield (Boston
Scientific, Natick, Mass) and TrapEase (Cordis, Bridgewa-
ter, NJ) filters are arguably among the most popular. The
Greenfield filter, which is available in a 12F introducer, has
been in use for 30 years and has been well studied. The
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394TrapEase filter, which is available in a much smaller intro-
ducer (6F), has been available since 2000, with a limited
number of studies.
Despite the popularity of these filtration devices, no
good guidelines are in place to help determine which filter
to use in any given situation. Our initial experience with the
TrapEase filter suggested a high incidence of filter throm-
bosis.11 In a retrospective series of 189 TrapEase filter
placements, we encountered three patients with early IVC
thrombosis/filter thrombosis presenting with symptoms
varying from mild bilateral lower extremity swelling to
compartment syndrome with phlegmasia cerulean dolens
and PE. Owing to the limitations of that retrospective
design, many questions were left unanswered after that
study. We have pursued some of these questions with a
prospective randomized study.
METHODS
This study was approved by the Investigational Review
Board at Maimonides Medical Center.
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(63 men, 93 women) with lower extremity deep vein
thrombosis (DVT) or at high risk of DVT based on the
exclusion and inclusion criteria reported in Table I. Ran-
domization was accomplished by a circulating nurse or the
patient randomly picked a prelabeled index card from an
envelope and resulted in 84 patients being assigned to the
stainless steel Greenfield filter (GF) and 72 to the TrapEase
filter (TF). Detailed medical history and demographic in-
formation were obtained from the patients or family mem-
bers and medical records. Patients were a mean age of 75
years (range, 38-101 years).
Filter insertion. Themethod of filter insertion has been
described in our prior publications.11,12 Briefly, a vena-
cavogram was performed before filter insertion through the
common femoral vein. Intraoperative fluoroscopy was ob-
tained to document filter position. Duplex scans of the IVC,
iliac veins, and lower extremity veinswere performed1week
of filter insertion in 73 patients to assess for the incidence of
femoral vein thrombosis related to percutaneous placement
through the femoral route and IVC filter thrombosis.
The 156 filters were inserted in the infrarenal position
by one group of surgeons at one institution using angio-
graphic guidance through the right common femoral vein
in 116 patients or the left common femoral vein in 40. The
most common reason for left common femoral vein access
was a clot in the right femoral or iliac vein.
Clinical evaluation and follow-up. All patients un-
derwent the relevant perioperative diagnostic studies, such
as venous duplex scan, ventilation/perfusion scan, and
computed tomography scan of the chest, as warranted by
their clinical situations. Postoperative follow-up consisted
of serial lower extremity and iliac vein/IVC duplex imaging
at day 1,7 days, every 3months for the first year, and then
every 6 months for the second year.
Clinical evaluation of the insertion site and the general
health status of the patients were performed 24 hours of
filter insertion and at subsequent clinic visits. Patients who
missed clinical appointments were interviewed by tele-
Table I. Selection criteria
Inclusion criteria
● Contraindication to anticoagulation with DVT/PE
● Failed anticoagulation with DVT/PE
● Trauma patient at high risk for DVT/PE
● High-risk procedure for TE with history of VTE
Exclusion criteria
● Age 18 years
● Preexisting filter
● Uncontrollable coagulopathy
● Vena cava diameter 30 mm
● Hypersensitivity to nickel, chromium, stainless steel
● Pregnancy or planning pregnancy 6 months
● Nonfemoral vein access for IVC filter placement
● Suprarenal IVC filter placement
DVT, Deep vein thrombosis; IVC, inferior vena cava; PE, pulmonary em-
bolism; TE, thromboembolism; VTE, venous thromboembolism.phone interviews to detect any potential complications.The study was interrupted five times (mean duration, 4
days; range, 1-11 days) due to lack of inventory.
During the duration of the study, 349 patients (143
men, 206 women; mean age, 75 years; range, 24-96 years)
were not randomized. Most of the patients who were not
randomized received GF (n  232) or TF (n  114), with
the exception of three patients who underwent placement
of a temporary retrievable Optease (OpF; Cordis) filter.
The choice of filter was determined by surgeon’s preference
or availability of the filter.
Statistical analysis. Demographics, indications, dura-
tion of follow-up, risk factors, and symptomatic complica-
tion in the randomized group (GF vs TF) were compared
using 2 test (WINKS version, TexaSoft Software). The
randomized and nonrandomized groups were also ana-
lyzed for similar categories for any statistical difference
using 2 analysis. A value of P  .05 was considered
statistically significant.
RESULT
Between July 2006 and November 2008, 156 patients
were randomized to receive 156 United States Food and
Drug Administration (FDA)-approved IVC filters. The indi-
cations for filter placement in the randomized and nonran-
domized groups are summarized in Table II. All patients in
the randomized group had lower extremity DVT except four
(2 in each group), in whom prophylactic filters were placed
due to hip fracture and history of venous thromboembolism.
The overall follow-up for both groups was 12 months
(range, 0-39 months). Serial lower extremity duplex imag-
ing was performed during the 28-month follow-up period
in 121 patients (78.2%), comprising 61 in GF and 60 in TF;
and 92 of 110 patients (84%) who survived 2 months
underwent lower extremity duplex imaging.
During the study, major symptomatic complication
occurred in five patients (6.94%) in the TF group and none
in the GF group. IVC thrombosis (IVCT) or iliac vein
thrombosis (IVT) was visualized in all five. In four of the
five patients, however, either the iliac vein or the IVC were
not clearly visualized due to either massive lower extremity
swelling extending up to the umbilical area or severe con-
tracture and bowel gas.
Symptomatic IVCT/IVT occurred a median of 14.8
days (range, 2-42 days) after IVCF insertion (Table III). It
was detected 2 weeks of filter insertion in four patients,
and on day 42 after insertion in one. Four patients pre-
sented with bilateral lower extremity swelling, and one
patient complained of bilateral groin pain without lower
extremity swelling. Acute renal failure was observed in one
patient. Clinical findings highly suggestive of phlegmasia
cerulea dolens were observed in another patient who was
found to have bilateral IVT, and the IVC was not clearly
visualized.
Further analysis of the data revealed a significantly
higher rate of IVCT in the TF group compared with GF
group (P .019 by 2). No filter migration, misplacement,
IVC perforation, or asymptomatic complications were ob-
ilure o
matic
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of the five patients with IVCT/IVT.
Although one of the purposes of the study was to
document the incidence of insertion site DVT between the
6F and the 12F sheath introducers, no such events were
observed in our study.
During this period, IVCT/IVT occurred in three pa-
tients in the nonrandomized group (GF, 1 of 232; TF, 2 of
114; OpF, 0 of 3). The lower incidence of symptomatic
events in the nonrandomized group is because these pa-
tients were not followed-up.
In the TF group, 31 of the 72 patients, including 2 of
the 5 patients with IVCT/IVT, were discharged with one
or combinations of anticoagulation therapy, including war-
farin, enoxaparin, or subcutaneous heparin (P  .632 by
Fisher exact test). In the GF group, 30 of 84 patients were
discharged with anticoagulation therapy. Statistical analysis
showed that anticoagulation after filter insertion was not
Table II. Patient demographics and indications
Variable Random
Age, mean  SD (range) y 75  13 (3
Sex, No.
Male 63
Female 93
Risk factors, No. (%)
Malignancy 38 (2
Deep vein thrombosis 152 (9
Indications, No. (%)
Contraindication to AC
Gastrointestinal bleeding 37 (2
Intracranial hemorrhage 12 (8
Failure of AC 29 (1
Free-floating clota 19 (1
PE with contraindication to AC 27 (1
Prophylaxis with h/o VTE 4 (3
Miscellaneousb 32 (2
AC, Anticoagulation; h/o, history of.
aFree-floating thrombus in infrainguinal vein with contraindication to or fa
bBed rest, femoral or hip fracture, heparin-induced thrombocytopenia, trau
Table III. Patients with inferior vena cava thrombusa
Pt Age Sex Medical history
1 97 M CHF, BPH, cholecystectomy PNA, GIB
2 77 M HTN, rec DVT, prostatectomy
meningioma-craniotomy
3 66 M APKD/ESRD, HTN, CAC, rec DVT
4 53 M Breast cancer, cholecystectomy, rec
DVT
5 83 M CVA, CAD, COPD, PHTN, GIB,
CKD, HR, PE
AC, Anticoagulation; APKD, adult polycystic kidney disease; BPH, benign
disease; CHF, congestive heart failure; CKD, chronic kidney disease; COP
deep veinous thrombosis; ESRD, end-stage renal disease; GIB, gastrointesti
thrombosis; IVT, iliac vein thrombosis; PE, pulmonary embolism; PHTN, p
aAll five patients were diagnosed with duplex imaging and treated symptom
bSuspected recurrent PE as the cause of death.significantly involved in the occurrence of higher rate ofIVCT/IVT in the TF group compared with the GF group
(P  .354 by 2).
The overall mortality during the entire follow-up was
42.3%: 66 of the 156 patients died, of which 34 were
in-patient deaths and 32 died after hospital discharge. The
30-daymortality was 13.5% (21 patients), with 10 deaths in
the TF group and 11 deaths in the GF group. At 12
months, 50 (TF, 19; GF, 31) of 156 patients had died, with
no statistical difference between the two groups (P 
0.173). Further mortality analysis revealed that most pa-
tients died of underlying medical conditions, including
metastatic disease, multisystem organ failure, sepsis, pneu-
monia, and questionable recurrent PE in one patient. No
deaths occurred because of filter-related complications,
except in one TF patient in whomwe believed recurrent PE
was the possible cause of death.
To demonstrate any statistical significance between the
two groups, the study was initially designed to recruit 360
Nonrandomized P value
) 75  15 (24-96)
.99
143 .92
206
59 (16.9) .05
318 (91.1) .008
78 (22) .41
26 (7) .53
51 (15) .16
31 (9) .16
60 (17.2) .98
31 (9) .005
77 (22) .4
f anticoagulation.
aortic transection, falls, seizure, metastatic cancer.
ation for VCF
Time to
occurrence
VCF-related
complication Outcome
ntraindicated 2 days IVT Died (unrelated)
ntraindicated 42 days IVCT/IVT Alive
e of AC 7 days IVCT Alive
e of AC 9 days IVCT Alive
rrent PE 14 days IVT Died (rec PE)b
ate hypertrophy; CAC, cerebral aneurysm clipping; CAD, coronary artery
onic obstructive pulmonary disease; CVA, cerebrovascular accident; DVT,
eding;HR, hip replacement;HTN, hypertension; IVCT, inferior vena cava
nary hypertension; PNA, pneumonia; VCF, vena cava filter.
y.ized
8-101
4.4)
7.4)
4)
)
9)
2)
7.3)
)
1)Indic
AC co
AC co
Failur
Failur
Recu
prost
D, chr
nal ble
ulmo
aticallpatients as predetermined by using a sample size routine Z
s had
had p
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percentage of incidence of each of the above listed compli-
cations) in both TF and GF in 2 years but it was prema-
turely concluded due to the interim results.
A comparison of the demographics and clinical out-
come between groups revealed the TF group had fewer
patients with malignancy than the GF group (P  .014;
Table IV). Considering malignancy as a procoagulant state
that would promote IVCT/IVT, one would have expected
a higher rate of IVCT/IVT in the GF group. Therefore,
factors other thanmalignancy are responsible for the higher
rate of IVCT/IVT in the TF group. Similarly, a comparison
of the risk factors between the patients in the TF groupwith
and without IVCT/IVT (Table V) revealed no statistical
significance.
A significant number of patients (n  349) were not
enrolled in the study (Table II). The major reason was
patient refusal (n 303) due to absolute lack of interest in
participating in a scientific study or inability to comply with
the follow-up requirement. Another reason was lack of
Table IV. Patient demographics and outcome in randomi
Category GF
Filters inserted, No. 84
Age, mean ya 75  13 (48
Sex
Male 31
Female 53
Risk factors, No. (%)
Malignancy 22 (26.2
Recent surgery 4 (4.76
CVA 10 (11.9
Miscellaneous 13 (15.5
TE event, No. (%)
Deep vein thrombosis 82 (97.6
Pulmonary embolism 18 (21.4
Follow-up, mean mona 12  11 (0-3
Duplex imaging, No. (%) 61 (72.6
Death 41 (35.7
CVA, Cerebrovascular accident; GF, Greenfield filter; TE, thromboembolis
aMean data are presented  standard deviation (range).
b83 patients who received GF had deep vein thrombosis, whereas 2 patient
c70 patients who received TF had deep vein thrombosis, whereas 2 patients
Table V. Comparison of risk factors between the
patients with and without inferior vena cava thrombus
(IVCT) and iliac vein thrombus (IVT) in the TrapEase
group
Variable IVCT/IVT No IVCT/IVT P value
Age, mean (range) 75 (53-97) 76 (38-97)
Sex, No. .01
Male 5 27
Female 0 40
Malignancy, No. 2 14 .65
Pulmonary embolism 1 12 .64
Cerebrovascular accident 1 1 .135availability of one of the filters, which resulted in severalinterruptions of the study (n  21 patients). To a lesser
degree, the exclusion criteria resulted in some patients
being excluded, including uncontrolled coagulopathy in 3,
preexisting filter in 3, pregnancy in 1, requirement for a
suprarenal IVC filter in 2, and nonfemoral vein access
through the internal jugular vein in 15 and the subclavian
vein in 1.
DISCUSSION
Some studies over the decades have demonstrated the
effectiveness and safety of IVC filters, but others have
reported a few but potentially severe complications that are
associated with filter use.13-18 The demonstrated safety and
effectiveness as well as the relatively benign insertion pro-
cess for IVC filter placement have led to the emergence and
FDA approval of several IVC filtration devices. On the
other hand, associated complications range from insertion-
site thrombosis to IVCT or subsequent PE. Modern fil-
ters1,2 have made steady improvements in design since their
inception with the Mobin Uddin filter (66% IVC occlu-
sion).19,20
Of the filtration devices currently in use, the Greenfield
filter continues to be among the most common and, argu-
ably, has the best safety profile. The Greenfield stainless
steel filter was introduced in 1994 and approved by the
FDA in 1995. It has a conical shape with six struts (4 of the
6 struts’ hooks point superiorly, and the 2 opposite strut
hooks point inferiorly) that are compressed into a 12F
carrier.
The TrapEase was approved in 2000. It is shaped into a
symmetrical double basket configuration that is connected
through with six side rails, each with both proximal and
distal hooks to provide filter anchoring. The two baskets,
which point in opposite directions, provide two levels of
clot filtration or capture. This filter is suited for patients
group
TF P value
72
76  13 (85-38) .5
.41
32
40
16 (22.20) .014
11 (15.3) .025
2 (2.78) .033
3 (4.17) .021
70 (97.2)c .876
13 (18.1) .599
12  10 (0-29)
60 (83.3) .11
25 (29.2) .385
, TrapEase filter.
a prophylactic filter.
rophylactic filters.zed
-101)
)
)
)
)
)b
)
3)
)
)
m; TFwith an IVC diameter of 30 mm. The TrapEase filter,
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its flexibility allows multiple routes for access, and its
smaller introducer size allows for placement of a superior
vena cava filter through a preexisting IVC filter.21
The history of the development of IVC filtration de-
vices reveals an evolution that has always centered on the
clot-trapping ability of the various devices and the long-
term caval patency/rate of IVC occlusion. The rate of
symptomatic IVC occlusion ranges from 0% to 12% for the
Greenfield22-32 to 2.4% to 8.3% for the TrapEase.33,34
In this study, we observed IVCT/IVT in five patients:
two had isolated bilateral IVT and three had documented
IVCT, with the involvement of the iliac veins observed in
one of the three. In the three patients where the IVC was
visualized, clot was found within the filter. Although clini-
cal findings of acute bilateral lower extremity swelling is
highly suggestive of IVC occlusion, the IVC was not visu-
alized in the two patients with isolated IVT due to bowel
gas and body habitus. None of the five patients were
deemed candidates for surgical or chemical thrombectomy.
Therefore, they were all managed symptomatically for lower
extremity swelling, and the IVCTwasmonitored with serial
lower extremity duplex imaging according to the study
protocol.
The observation of a higher rate of IVCT in patients
who received the TrapEase filter in our prior retrospective
study as well as in this current study has prompted us to
further analyze our data to help explain this occurrence.
However, a critical analysis of our data (especially the
demographics of the five patients with IVCT/IVT) re-
vealed no common underlying patient specific factor(s) or
subset of patients who are at increased risk for IVCT/IVT
with the TrapEase filter. Consequently, we are more in-
clined to attribute the occurrence of IVCT/IVT to filter-
related factors, as supported by numerous studies, rather
than patient-related factors.
On the other hand, Linneman et al35 suggested an
increased risk of IVCT in patients with lupus anticoagulant,
malignancy, or IVC abnormality. This observation is not
supported by our data: two of the five patients with IVCT/
IVT had malignancy or history of malignancy at the time of
filter insertion. Moreover, only 2 of the 38 patients with
malignancy had IVCT/IVT (Tables IV and V). None of
the five patients had a history of inherited thrombophilia,
and venacavogram did not reveal any IVC abnormalities.
However, despite the lack of any obvious underlying
patient-specific factor that may preclude the use of the IVC
TrapEase filter in any particular group of patients, in our
practice, we have limited its use to patients with elevated
international normalized ratio 2 at the time of filter
insertion. This is simply because of the small but significant
risk of postoperative bleeding, which may be observed in
patients who receive filters with a larger introducer sheath
such as in the Greenfield filter.
Several mechanisms for IVC filter thrombosis have
been proposed from various studies. One mechanism is the
hemodynamics of flow disturbance. As demonstrated by
Harlal et al,36 the TrapEase tends to exhibit more flowdisturbance than the Greenfield due to the formation of
stagnation or recirculation zone with partial clot entrap-
ment. This may be a consequence of a more drastic slant
angle that results in shorter filter profile. The shorter con-
ical filter profile, as in TrapEase, has been shown to pro-
mote flow separation from clot surface, which results in the
formation of a thrombotic zone. The Greenfield, on the
other hand, has a shallow slant angle that prevents flow
separation along the clot surface, resulting in a smaller
thrombotic zone.
Volumetric analysis shows the umbrella-type structure
that is common to filters such as the TrapEase and Mobin-
Uddin exhibits unfavorable hemodynamics because it pro-
motes the lodging of clot along the vessel wall. This creates
stagnation zones along the vessel wall that further contrib-
ute to more clot formation.37 The clot tends to lodge along
the inferior umbrella of the TrapEase before moving to the
superior basket, therefore creating large stagnation zones
downstream of the filter. This observation is also supported
by Leask et al,38 in which they observed a large region of
flow stagnation associated with the use of the TrapEase. As
demonstrated by Wessler et al,39 these stagnation zones or
low-velocity flow-reversal zones have also been linked to
thrombosis. The high shear gradient generated by the high
turbulence, as seen in the TrapEase, has also been dem-
onstrated to promote clot formation and red blood cell
destruction.40,41 On the basis of these proposed mecha-
nisms, it appears that the TrapEase creates a flow field
that induces clot formation, which helps to explain the
increased rate of thrombosis observed in our prior retro-
spective study and in the current prospective study.
CONCLUSIONS
These results show there is a higher rate of symptomatic
IVC filter/iliac vein thrombosis associated with TrapEase
filter placement. However, we suggest the TrapEase filter
still has a clinical role to play in preventing thromboembo-
lism in selected patients, especially those who are coagulo-
pathic. Interestingly, to the best of our knowledge, this is
the first randomized prospective study comparing IVC
filters since their inception in 1967.
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